A new report in Open Forum Infectious Diseases details the significant increase of the Babesia season in New England since ...

Replimune (REPL) stock plummets as report suggests FDA’s top regulator of cancer drugs intervened in rejecting its lead asset ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225) has been approved to initiate by both ...

Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN022, an independently developed innovative bispecific antibody-drug conjugate (ADC) ...

Q2 2025 Earnings Call Transcript August 1, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Q2 2025 Earnings Call Transcript July 31, 2025 Teleflex Incorporated misses on earnings expectations. Reported EPS is $2.77 EPS, expectations were $3.36. Operator: Good morning, ladies and gentlemen, ...

Wealth Enhancement reports that vacation homes are reshaping U.S. real estate, with over 6 million second homes concentrated ...

Revalesio, a clinical-stage biopharmaceutical company developing treatments for acute and chronic neurological disorders, today announced that the U.S. Food and Drug Administration has granted Fast ...

• Key Intrahepatic cholangiocarcinoma pipeline therapies in various stages of development include Zanidatamab, Derazantinib, MIV-818, Bemarituzumab, KIN-3248, TYRA-200, Nelitolimod, and others.

US senator Ron Wyden is demanding that the Department of Homeland Security investigate reports of agents being reassigned to ...

Opus Genetics partners with the Global RDH12 Alliance to advance gene therapy for inherited retinal disease, aiming for FDA ...

AngioDynamics has enrolled the first subject in the AMBITION BTK trial designed to assess the Auryon Atherectomy System.